Proactive Investors - Run By Investors For Investors

Immunovaccine breaking ground, says Mackie, as it rates stock 'speculative buy'

Mackie reckons the firm is 'breaking ground' and targets C$2.80 for the shares..
Immunovaccine breaking ground, says Mackie, as it rates stock 'speculative buy'
The firm is operating in the field of immunology..

Broker Mackie repeated a 'speculative buy' stance on Immunovaccine Inc (TSE:IMV) following news that it was advancing its cancer vaccine into a Phase I trial.

The biotech announced an expansion of its ongoing collaboration with UConn Health  - part of Immunovaccine’s DPX-NEO program.

This is assessing the anti-cancer activity of patient specific epitopes (the part of molecule which is the target of an immune response) developed at UConn Health and formulated in Immunovaccine's proprietary delivery system.

“The potential of neoepitope-based therapies to trigger anti-cancer immune responses tailored to the unique biology of each patient’s disease could be an oncology treatment game-changer,” said Frederic Ors, Immunovaccine’s chief executive today.

Mackie agrees the firm is 'breaking ground'  and targets C$2.80 for the shares, against a current price of C$2.13 - up over 11% on the day.

DPX-NEO should diversify the group's pipeline once it enters a Phase I study, says analyst Andre Uddin, who adds there are multiple catalysts ahead for the group.

"IMV has been up 181% YTD and our call has generated a 208% return since we launched coverage," he notes.

View full IMV profile View Profile

ImmunoVaccine Timeline

Related Articles

woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half
researcher using microscope
September 28 2017
A total of £6mln is expected to come via a share placing and up to a further £2mln through an open offer of stock to existing investors

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use